GIA
CRL icon

Granite Investment Advisors’s Charles River Laboratories CRL Stock Holding History

Granite Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$613K Sell
1,485
-110
-7% -$45.7K 0.1% 124
2021
Q2 		$590K Buy
+1,595
New +$533K 0.09% 125

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Granite Investment Advisors's CRL Position: Q3 2021 in Review

Granite Investment Advisors reduced its Charles River Laboratories (CRL) stake by 6.9% in Q3 2021, selling an estimated $45.7K and leaving 1,485 shares worth $613K. The position accounts for 0.1% of the portfolio, ranked #124.

Granite Investment Advisors first reported a position in CRL in Q2 2021 and has held it in 2 quarters since. 677 funds tracked by Wall St. Rank hold CRL as of Q3 2021.

  • Granite Investment Advisors held 1,485 shares of Charles River Laboratories worth $613K as of Q3 2021.
  • Granite Investment Advisors sold 110 Charles River Laboratories shares in Q3 2021, an estimated $45.7K.
  • Charles River Laboratories made up 0.1% of Granite Investment Advisors's portfolio in Q3 2021, its #124 holding.
  • Granite Investment Advisors first reported a position in Charles River Laboratories in Q2 2021 and has held it in 2 quarters since.
  • 677 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2021.

Based on Granite Investment Advisors's 13F filing for Q3 2021, filed 8 Nov 2021.